Tuesday, Medtronic Plc ( MDT )  reported first-quarter 2025 sales of $7.92 billion, beating the consensus of $7.89 billion.

The medical device maker reported adjusted EPS of $1.23, beating the consensus of $1.20. Revenue increased 2.8% year over year, as reported, and 5.3% organic.

The company said multiple franchises delivered, with accelerating growth in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes.

Also Read: Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers.

Cardiovascular segment revenue reached $3.01 billion, up 5.5% year over year as reported, and increased 6.9% organically, with high-single-digit increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic and a mid-single-digit increase in Coronary & Peripheral Vascular, all on an organic basis.

Neuroscience revenues of $2.32 billion increased 4.4% as reported and 5.3% organically, with a low-double-digit increase in Neuromodulation, a mid-single-digit increase in Cranial & Spinal Technologies, and a low-single-digit increase in Specialty Therapies, all on an organic basis.

Medical Surgical revenue of $1.99 billion decreased by 0.4% as reported and increased by 1.0% organically, with a low-single-digit increase in Surgical & Endoscopy and flat results in Acute Care & Monitoring, both on an organic basis. Diabetes revenue of $647 million increased by 11.8%, as reported, and by 12.6% organic.

“Overall revenue outperformance flowed through to the bottom line, with adjusted EPS ahead of expectations,” said Gary Corona, Medtronic’s interim chief financial officer. “We’re raising our guidance today as we expect to sustain growth from new product introductions, continue to make the investments to support those launches, and deliver on our commitment to restore earnings power.”

Guidance: Medtronic ( MDT ) revised its fiscal year 2025 adjusted EPS guidance to $5.42 – $5.50, compared to prior guidance of $5.40 – $5.50 and consensus of $5.44. The company sees fiscal year 2025 organic revenue growth of 4.5% – 5% compared to prior guidance of 4% – 5%.

Price Action: MDT stock is up 0.51% at $85.25 during the premarket session at last check Tuesday.

Read Next:

GM Cuts Over 1,000 Jobs In Software And Services Division, Seeks Cost Savings: Report.